My Top 3 Pharmaceutical Stocks For 2015: GlaxoSmithKline plc, AstraZeneca plc And BTG plc

GlaxoSmithKline plc (LON: GSK), AstraZeneca plc (LON: AZN) and BTG plc (LON: BTG) could have a great 2015

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

2014 has been something of a mixed year for investors in pharmaceutical stocks. While the likes of BTG (LSE: BTG) and AstraZeneca (LSE: AZN) (NYSE: AZN.US) have easily beaten the FTSE 100, being up 30% and 29% respectively versus a fall of 2% for the wider index, life hasn’t been so enjoyable for GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US).

Indeed, the largest of the three companies by market capitalisation has seen its share price fall by 10% this year, with allegations of bribery and competition from generics dampening sentiment in the stock.

Looking to 2015, though, I believe that all three companies could post strong gains and outperform the wider index next year. Here’s why.

GlaxoSmithKline

Restructuring could be on the cards at GlaxoSmithKline, with the company mulling over the spin-off of its HIV unit, ViiV Healthcare. This could boost sentiment, since ViiV has huge potential and could offer a stunning growth profile over the medium term.

Meanwhile, the allegations of bribery that have pegged back sentiment in GlaxoSmithKline during 2014 could prove to be less of a problem next year. That’s because the company has been fined around £300 million by Chinese authorities and so it will be aiming to draw a line under the matter.

Furthermore, with shares in the company trading on a price to earnings (P/E) ratio of just 15.5, they seem to offer good relative value. In addition, a yield of 5.6% could boost demand for the shares and mean that they have a strong 2015.

AstraZeneca

Even if another bid from Pfizer or a different sector peer is not forthcoming, AstraZeneca could continue its excellent performance of 2014 into 2015 and beyond. That’s because the main reason for its turnaround has been a vast acquisition programme that is turning the company’s drugs pipeline around.

Indeed, while it was once viewed as its major weakness, AstraZeneca’s drugs pipeline is now seen as a source of growth moving forward. And, with considerable financial firepower and superb cash flow, more acquisitions seem inevitable and they could drive sentiment in the stock much higher.

Trading on a P/E ratio of 16.8 and yielding 3.7%, AstraZeneca still seems to offer good relative value and income potential. Combined with improving growth prospects, 2015 could be another great year for investors in the stock.

BTG

Today’s results from BTG were highly encouraging and show that 2015 could be another fantastic year for the company. Indeed, partly as a result of acquisitions in its interventional medicine unit and impressive growth in its specialty pharmaceuticals business, it reported higher profit for the first half of the current year (£37.6 million versus £32.7 million last year) and stated that full-year results look set to be at the top end of analysts’ forecasts.

Furthermore, with BTG being expected to increase earnings by a whopping 48% next year, the fact that the company expects the current momentum to continue is clearly excellent news for investors.

In addition, shares in BTG trade on a P/E ratio of 50.9 which, when combined with such a strong growth rate, equates to a price to earnings growth (PEG) ratio of just over 1. As such, BTG seems to offer growth at a very reasonable price and could have another stunning year of share price growth in 2015.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of AstraZeneca and GlaxoSmithKline. The Motley Fool UK has recommended BTG and GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Illustration of flames over a black background
Investing Articles

2 red-hot UK growth stocks to consider buying in April

These two growth stocks are performing well, but can they continue to deliver for investors through 2024 and beyond?

Read more »

Charticle

Is JD Sports Fashion one of the FTSE 100’s best value stocks? Here’s what the charts say!

The JD Sports Fashion share price remains a wild ride during the first quarter. Could it be one of the…

Read more »

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »